Exclusive Summary

• - Fully off-patent worldwide, with broad generic entry since 2009–2010, enabling rapid market access
• - Large and aging BPH/LUTS population (>250 million men), with 0.4 mg as the standard dose in US/EU and steady demand growth
• - Recommended as first-line by WHO/EAU/AUA, offering fast onset and good tolerability, and fits well in combination therapy
• - US registration and FDA-GMP backing provide strong quality/compliance credentials for tenders and private channels
• - Generic pricing typically 70–95% below originator, substantially reducing payer and patient costs